A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)

Trial Details

NCT ID
NCT06785636
Phase
PHASE1 / PHASE2
Sponsor
Pathos AI, Inc.
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Pocenbrodib
  • Pocenbrodib and Darolutamide
Locations (sample)
  • Fountain Valley, California, United States|33.70918,-117.95367
  • Los Alamitos, California, United States|33.80307,-118.07256
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Miami, Florida, United States|25.77427,-80.19366
  • Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

  • ≥18 years of age
  • Histologic documentation of prostate adenocarcinoma
  • Metastatic disease, documented by imaging. Imaging performed within 56 days prior to Screening is acceptable
  • 1b / 2a Exclusion Criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →